ArticleFrontiers in oncology2022
Disease Burden, Risk Factors, and Trends of Leukaemia: A Global Analysis.
Article in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
56 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- A meta-analysis and expression profiling of DNA repair gene polymorphisms in leukemia.Frontiers in oncology · 2026Pooled it
- Prevalence and associated factors of Leukemia in Africa: A systematic review and meta-analysis.PloS one · 2026Pooled it
- Advances in Leukemia detection and classification: A Systematic review of AI and image processing techniques.F1000Research · 2024Pooled it
- Impact of Spiritual Care Education on Leukemia Patients' Post-traumatic Growth and Resilience in Iran: A Randomized Controlled Trial.Journal of religion and health · 2026Trial
- Integrated computational and experimental identification of a novel ML-IAP-targeting peptide with antiproliferative activity in leukaemia cells.Journal of enzyme inhibition and medicinal chemistry · 2026Article
- Oleanolic acid in the fight against cancer: a multifaceted natural strategy for modern oncology.Molecular diversity · 2026Review
- Review
- Selectively Targeting Leukemic MOLT-4 Cells by MTX-cIBR Conjugate: Mechanism of Action and Cellular Entry.Life (Basel, Switzerland) · 2026Article
- Article
- Lactylation in cancer: molecular mechanisms and advances in clinical study.Molecular cancer · 2026Review
- Linalool in cancer pharmacology: pharmacokinetic limitations and preclinical cytotoxic evidence for translational development.Frontiers in pharmacology · 2026Review
- Trends in incidence and mortality of acute and chronic leukaemias in Brazil: challenges and advances over three decades.Ecancermedicalscience · 2026Article
- Leukemia in users of contemporary hormonal contraception: A nationwide registry-based cohort study among premenopausal women in Denmark.PLoS medicine · 2026Article
- The emerging role of echocardiography-based techniques in cardio-onco-hematology.Frontiers in oncology · 2026Review
- Association of Donor and Recipient Duffy and Kidd Genotypes with GVHD in Leukemia Patients Undergoing Bone Marrow Transplantation.Iranian journal of pathology · 2026Article
- Late-stage leukemias in aging populations: a public health call for integrated and personalized care models.Annals of medicine and surgery (2012) · 2026Review
- Burden of Hematological Malignancies in East Asia from 1990 to 2021.Journal of clinical medicine · 2025Article
- Bridging the gap: the need for community-engaged research on blood cancer self-management experiences among South Asians.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025Article
- Monoclonal Antibodies as a Breakthrough in Personalised Leukaemia Therapy: What Pharmacists and Doctors Should Know.Pharmacy (Basel, Switzerland) · 2025Review
- Identification of potential natural BCL-2 inhibitors for leukemia through an integrated virtual screening approach.BMC pharmacology & toxicology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Leukaemia accounted for approximately 2.5% of all new cancer incidence and 3.1% of cancer-related mortality. The investigation of its risk factors and epidemiologic trends could help describe the geographical distribution and identify high-risk population groups. This study aimed to evaluate the global incidence, mortality, associated risk factors, and temporal trends of leukaemia by sex, age, and country. We extracted incidence and mortality of leukaemia from
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.